Roche Abandons Emugrobart – Clears Path for Scholar Rock’s Apitegromab to Dominate SMA
Roche halts emugrobart development, clearing path for Scholar Rock's apitegromab to dominate SMA muscle therapy market. Cantor sees multi-billion potential.
/ 1659 items
#XY↓
Lilly’s Retatrutide Crushes Weight Loss Goals in First Phase 3 Trial – Wall Street Says It’s a ‘Key Pillar’ for Growth
Eli Lilly’s retatrutide delivered up to 2.0% A1C reduction and 16.8% weight loss (36.6 lbs) in its first Phase 3 trial for type 2 diabetes. Analysts call it a key growth driver for Lilly with strong results vs Mounjaro.
Schizophrenia Focus Pays Off — Canaccord Starts MPLT at Buy, Sees $35 Value on ML-007 Alone
Canaccord Genuity starts coverage on MapLight Therapeutics (MPLT) with Buy rating and $35 price target.
Elliott Takes Big Stake in Invisalign Maker Align Technology to Boost Slumping Stock
Activist investor Elliott Investment Management takes major stake in Align Technology, Invisalign maker, to push for stock price gains amid post-pandemic slump.
MoonLake Immunotherapeutics Gets Bullish Upgrade: Analyst Sees $40 Target as FDA Path Clears for Sonelokimab in HS
Rothschild Redburn upgrades MoonLake to Buy from Neutral. Sonelokimab's FDA path for HS clears major hurdle; seen as best-in-class contender attractive to big pharma.
Novo Nordisk Faces More Pain: Bernstein Initiates Underperform Coverage
Bernstein initiates Underperform on Novo Nordisk, citing endless earnings downgrades, weak catalysts, U.S. price deflation, and 2032 patent cliff risks.